As the patent expiration of Keytruda, Merck’s iconic blockbuster cancer drug, looms on the horizon, the U.S. pharmaceutical behemoth is strategically intensifying its dealmaking endeavors. One such pursuit has led Merck to the doorstep of Swiss biotech firm MoonLake Immunotherapeutics, underlining a critical juncture in the competitive biotech landscape. Merck’s overture, a bid exceeding $3 […]
